Alpha- Antitrypsin Deficiency- Epidemiology Forecast to 2027

  • ID: 4330786
  • Report
  • 50 pages
  • DelveInsight
1 of 3
The "Alpha- Antitrypsin Deficiency (AATD) - Epidemiology Forecast to 2027" report provides a comprehensive analysis of the disease epidemiology in the 7MM (United States, Germany, France, Italy, Spain, UK and Japan). The study period of the report is 2017-2027. This report provides understanding of the patients affected, diagnostic patterns, treatment trends and unmet medical needs.

The overview part of the report helps to develop a deep insights regarding AATD, its symptoms, pathophysiology and treatment approaches. The epidemiology section gives the detail about the total patient pool of AATD. It also includes the explanation of changing trends of epidemiology by exploring numerous studies and views of key opinion leaders.

The disease epidemiology covered in the report is segmented into two parts: Population at the risk of developing AATD on the basis of allele [PiSS, PiSZ, PiZZ) and Prevalent cases of AATD in 6 Major Markets (United States and EU5 (Germany, Spain, Italy, France and United Kingdom). Population at risk of Alpha-1-Antitrypsin Deficiency has been calculated on the basis of direct epidemiological approach that uses findings of genetic epidemiological surveys. As AATD is quite rare in Japan, the report features the diagnosed population of AATD in Japan.

Report Scope
  • The report covers detailed overview of Alpha- Antitrypsin Deficiency (AATD) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Alpha- Antitrypsin Deficiency (AATD) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the population at risk of developing AATD and prevalence of AATD in 6MM and diagnosed population of AATD in Japan
Key strengths
  • 10 Year Forecast of Alpha- Antitrypsin Deficiency (AATD) epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Alpha- Antitrypsin Deficiency (AATD)
  • Prevalent population of AATD and population at risk of developing AATD
Key assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Report Introduction

2. Alpha Antitrypsin Deficiency Epidemiology Overview at a Glance
2.1. Prevalent Population of Alpha Antitrypsin Deficiency in 20
2.2. Prevalent Population of Alpha Antitrypsin Deficiency in 20

3. Disease Background and Overview: Alpha Antitrypsin Deficiency
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Genetic Inheritance of Alpha Antitrypsin Deficiency
3.6. Pathophysiology
3.7. Complications
3.8. Diagnosis
3.9. Treatment
3.10. Diagnostic Delay

4. Epidemiology and Patient Population
4.1. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM
4.2. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 7MM – By Region
4.3. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM – Distribution (2016)
4.4. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM – Distribution (2027)
4.5. Epidemiology of Alpha-1-Antitrypsin Deficiency- By Country
4.5.1. United States
4.5.1.1. Assumptions and Rationale
4.5.1.2. Population at risk of Alpha Antitrypsin Deficiency in United States
4.5.1.3. Prevalent Population of Alpha Antitrypsin Deficiency
4.5.2. EU
4.5.2.1. Assumptions and Rationale
4.5.2.2. Germany
4.5.2.2.1. Population at risk of Alpha Antitrypsin Deficiency in Germany
4.5.2.2.2. Prevalent Population of Alpha Antitrypsin Deficiency in Germany
4.5.2.3. France
4.5.2.3.1. Population at risk of Alpha Antitrypsin Deficiency in France
4.5.2.3.2. Prevalent Population of Alpha Antitrypsin Deficiency in France
4.5.2.4. Italy
4.5.2.4.1. Population at risk of Alpha Antitrypsin Deficiency in Italy
4.5.2.4.2. Prevalent Population of Alpha Antitrypsin Deficiency in Italy
4.5.2.5. Spain
4.5.2.5.1. Population at risk of Alpha Antitrypsin Deficiency in Spain
4.5.2.5.2. Prevalent Population of Alpha Antitrypsin Deficiency in Spain
4.5.2.6. United Kingdom
4.5.2.6.1. Population at risk of Alpha Antitrypsin Deficiency in UK
4.5.2.6.2. Prevalent Population of Alpha Antitrypsin Deficiency in UK
4.5.3. Japan
4.5.3.1. Diagnosed Population of Alpha Antitrypsin Deficiency in Japan

5. Appendix

6. Report Methodology
6.1. Sources Used

7. Consulting Services

8. Disclaimer

9. About the Publisher

List of Tables:
Table 1: Total Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6 MM (2016-2027)
Table 2: Prevalent Population of Alpha-1-Antitrypsin Deficiency in 7MM (2016-2027)
Table 3: Population at risk of Alpha Antitrypsin Deficiency in United States (2016-2027)
Table 4: Prevalent Population of Alpha Antitrypsin Deficiency in United States (2016-2027)
Table 5: Population at risk of Alpha Antitrypsin Deficiency in Germany (2016-2027)
Table 6: Prevalent Population of Alpha Antitrypsin Deficiency in Germany (2016-2027)
Table 7: Population at risk of Alpha Antitrypsin Deficiency in France (2016-2027)
Table 8: Prevalent Population of Alpha Antitrypsin Deficiency in France (2016-2027)
Table 9: Population at risk of Alpha Antitrypsin Deficiency in Italy (2016-2027)
Table 10: Prevalent Population of Alpha Antitrypsin Deficiency in Italy (2016-2027)
Table 11: Population at risk of Alpha Antitrypsin Deficiency in Spain (2016-2027)
Table 12: Prevalent Population of Alpha Antitrypsin Deficiency in Spain (2016-2027)
Table 13: Population at risk of Alpha Antitrypsin Deficiency in United Kingdom (2016-2027)
Table 14: Prevalent Population of Alpha Antitrypsin Deficiency in United Kingdom (2016-2027)
Table 15: Diagnosed Population of Alpha Antitrypsin Deficiency in Japan (2016-2027)

List of Figures:
Figure 1: Pathogenesis of Alpha Antitrypsin Deficiency
Figure 2: Diagnostic Algorithm of Alpha Antitrypsin Deficiency
Figure 3: General Treatment of Alpha Antitrypsin Deficiency
Figure 4: Total Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6 MM (2016-2027)
Figure 5: Prevalent Population of Alpha-1-Antitrypsin Deficiency in 7MM (2016-2027)
Figure 6: Population at risk of Alpha Antitrypsin Deficiency in United States (2016-2027)
Figure 7: Prevalent Population of Alpha Antitrypsin Deficiency in United States (2016-2027)
Figure 8: Population at risk of Alpha Antitrypsin Deficiency in Germany (2016-2027)
Figure 9: Prevalent Population of Alpha Antitrypsin Deficiency in Germany (2016-2027)
Figure 10: Population at risk of Alpha Antitrypsin Deficiency in France (2016-2027)
Figure 11: Prevalent Population of Alpha Antitrypsin Deficiency in France (2016-2027)
Figure 12: Population at risk of Alpha Antitrypsin Deficiency in Italy (2016-2027)
Figure 13: Prevalent Population of Alpha Antitrypsin Deficiency in Italy (2016-2027)
Figure 14: Population at risk of Alpha Antitrypsin Deficiency in Spain ( (2016-2027)
Figure 15: Prevalent Population of Alpha Antitrypsin Deficiency in Spain (2016-2027)
Figure 16: Population at risk of Alpha Antitrypsin Deficiency in United Kingdom (2016-2027)
Figure 17: Prevalent Population of Alpha Antitrypsin Deficiency in United Kingdom (2016-2027)
Figure 18: Diagnosed Population of Alpha Antitrypsin Deficiency in Japan (2016-2027)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll